Internal Medicine in Stayton, OR
3 verified internal medicine doctors in Stayton.
Internists specialize in the prevention, diagnosis, and treatment of adult diseases, often coordinating complex or chronic conditions across multiple systems.
NPPES tenure ≠ clinical experience. "Years on NPPES" is time since the physician first registered a National Provider Identifier, not time practicing medicine. Verify current license status with the state medical board.
Dr. Michael Chen, MD
Internal Medicine
CMS Open Payments· $150.34 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$150.34
Total received
6
Transactions
4
Paying companies
Top paying companies
Among the 183,896 internal medicine doctors we've analyzed, about 37% received any industry payment (median $195 among those who did). This doctor's total ranks around the 80th percentile of that group.
Benchmark reflects doctors we've analyzed, not all US internal medicine doctors.
Payments to Michael Chen do not imply any wrongdoing. Many are meals, education, or research support.
Dr. George Degner, MD
Internal Medicine
CMS Open Payments· $891.45 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$891.45
Total received
42
Transactions
23
Paying companies
Top paying companies
Among the 183,896 internal medicine doctors we've analyzed, about 37% received any industry payment (median $195 among those who did). This doctor's total is higher than 91% of that group — among the highest recipients.
Benchmark reflects doctors we've analyzed, not all US internal medicine doctors.
Payments to George Degner do not imply any wrongdoing. Many are meals, education, or research support.
Dr. Kim Dang, MD
Internal Medicine
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.